U.S. flag

An official website of the United States government

NM_000251.3(MSH2):c.2005G>T (p.Gly669Cys) AND Hereditary cancer-predisposing syndrome

Germline classification:
Likely pathogenic (2 submissions)
Last evaluated:
Jan 30, 2024
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000566809.8

Allele description [Variation Report for NM_000251.3(MSH2):c.2005G>T (p.Gly669Cys)]

NM_000251.3(MSH2):c.2005G>T (p.Gly669Cys)

Gene:
MSH2:mutS homolog 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
2p21
Genomic location:
Preferred name:
NM_000251.3(MSH2):c.2005G>T (p.Gly669Cys)
HGVS:
  • NC_000002.12:g.47475270G>T
  • NG_007110.2:g.77147G>T
  • NM_000251.3:c.2005G>TMANE SELECT
  • NM_001258281.1:c.1807G>T
  • NP_000242.1:p.Gly669Cys
  • NP_000242.1:p.Gly669Cys
  • NP_001245210.1:p.Gly603Cys
  • LRG_218t1:c.2005G>T
  • LRG_218:g.77147G>T
  • LRG_218p1:p.Gly669Cys
  • NC_000002.11:g.47702409G>T
  • NM_000251.1:c.2005G>T
  • NM_000251.2:c.2005G>T
Protein change:
G603C
Links:
dbSNP: rs63751668
NCBI 1000 Genomes Browser:
rs63751668
Molecular consequence:
  • NM_000251.3:c.2005G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001258281.1:c.1807G>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000676071Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Likely pathogenic
(Jan 30, 2024)
germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

Citation Link,

SCV000690038Color Diagnostics, LLC DBA Color Health
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Oct 17, 2018)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes.

Losi L, Di Gregorio C, Pedroni M, Ponti G, Roncucci L, Scarselli A, Genuardi M, Baglioni S, Marino M, Rossi G, Benatti P, Maffei S, Menigatti M, Roncari B, Ponz de Leon M.

Am J Gastroenterol. 2005 Oct;100(10):2280-7.

PubMed [citation]
PMID:
16181381

Germline mutation analysis of MLH1 and MSH2 in Malaysian Lynch syndrome patients.

Zahary MN, Kaur G, Abu Hassan MR, Singh H, Naik VR, Ankathil R.

World J Gastroenterol. 2012 Feb 28;18(8):814-20. doi: 10.3748/wjg.v18.i8.814.

PubMed [citation]
PMID:
22371642
PMCID:
PMC3286145
See all PubMed Citations (5)

Details of each submission

From Ambry Genetics, SCV000676071.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

The c.2005G>T variant (also known as p.G669C), located in coding exon 12 of the MSH2 gene, results from a G to T substitution at nucleotide position 2005. The amino acid change results in glycine to cysteine at codon 669, an amino acid with highly dissimilar properties. However, this change occurs in the last base pair of coding exon 12, which makes it likely to have some effect on normal mRNA splicing. This variant has been identified in an additional proband whose Lynch syndrome-associated tumor demonstrated loss of MSH2/MSH6 expression by IHC (external laboratory communication) and, in a study that quantified tumor characteristics to assess pathogenicity for germline mismatch repair gene variants, this variant was reported in an individual whose Lynch syndrome-associated tumor demonstrated loss of MSH2/MSH6 expression on immunohistochemistry (IHC; Ambry internal data; Li S et al. J. Med. Genet. 2020 Jan;57:62-69). In a massively parallel cell-based functional assay testing susceptibility to a DNA damaging agent, 6-thioguanine (6-TG), this variant was reported to be functionally neutral (Jia X et al. Am J Hum Genet, 2021 Jan;108:163-175). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and will result in the creation or strengthening of a novel splice donor site. Based on the majority of available evidence to date, this variant is likely to be pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Color Diagnostics, LLC DBA Color Health, SCV000690038.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024